MEDANTA

Global Health Share Price

₹1,071.65 -20.25 (-1.85%)

21 Nov, 2024 14:00

SIP TrendupStart SIP in MEDANTA

Start SIP

Performance

  • Low
  • ₹1,057
  • High
  • ₹1,090
  • 52 Week Low
  • ₹889
  • 52 Week High
  • ₹1,514
  • Open Price₹1,073
  • Previous Close₹1,092
  • Volume198,531

Investment Returns

  • Over 1 Month + 0.37%
  • Over 3 Month -0.92%
  • Over 6 Month -23.68%
  • Over 1 Year + 19.49%
SIP Lightning

Smart Investing Starts Here Start SIP with Global Health for Steady Growth!

Invest Now

Global Health Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 59
  • PEG Ratio
  • 3
  • Market Cap Cr
  • 28,783
  • P/B Ratio
  • 9.9
  • Average True Range
  • 36.62
  • EPS
  • 18.17
  • Dividend Yield
  • 0
  • MACD Signal
  • 1.78
  • RSI
  • 55.16
  • MFI
  • 59.26

Global Health Financials

Global Health Technicals

EMA & SMA

Current Price
₹1,071.65
-20.25 (-1.85%)
pointer
  • stock-down_img
  • Bullish Moving Average 7
  • stock-up_img
  • Bearish Moving Average 9
  • 20 Day
  • ₹1,069.59
  • 50 Day
  • ₹1,079.30
  • 100 Day
  • ₹1,113.16
  • 200 Day
  • ₹1,108.62

Resistance and Support

1086.68 Pivot Speed
  • R3 1,139.17
  • R2 1,119.93
  • R1 1,105.92
  • S1 1,072.67
  • S2 1,053.43
  • S3 1,039.42

What's your outlook on Global Health?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Global Health Ltd. is an Australian healthcare technology company providing software solutions that connect clinicians and consumers. Its applications streamline healthcare delivery across hospitals, GPs, and allied health sectors, improving health outcomes through secure data sharing and connected health records.

Global Health has an operating revenue of Rs. 3,458.86 Cr. on a trailing 12-month basis. An annual revenue growth of 21% is outstanding, Pre-tax margin of 19% is great, ROE of 16% is good. The company has a reasonable debt to equity of 10%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 85 which is a GOOD score indicating consistency in earnings, a RS Rating of 35 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 30 indicates it belongs to a strong industry group of Medical-Hospitals and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Global Health Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-08 Quarterly Results
2024-05-17 Audited Results
2024-02-08 Quarterly Results
2023-11-09 Quarterly Results

Global Health F&O

Global Health Shareholding Pattern

33.04%
9.59%
0.59%
12.21%
6.55%
38.02%

About Global Health

  • NSE Symbol
  • MEDANTA
  • BSE Symbol
  • 543654
  • Chairman & Managing Director
  • Dr. Naresh Trehan
  • ISIN
  • INE474Q01031

Similar Stocks to Global Health

Global Health FAQs

Global Health share price is ₹1,071 As on 21 November, 2024 | 13:46

The Market Cap of Global Health is ₹28783.2 Cr As on 21 November, 2024 | 13:46

The P/E ratio of Global Health is 59 As on 21 November, 2024 | 13:46

The PB ratio of Global Health is 9.9 As on 21 November, 2024 | 13:46

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23